Thus, future studies based on motifs enrichment analysis and chromatin immunoprecipitation will be required to clarify the contribution of the different transcription factors rather than c-MYC in PDA chemoresistance together with complementary studies with other chemotherapeutic agents to validate this synergistic effect and bypass its mechanism of resistance. Here, MYC is linked to Patent ductus arteriosus.